

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

comparison of the effect of Fingolimode and Betaferon (high dose) in decreasing the symptoms and relapse rates of MS patients whose treatment with Betaferon (low dose) was failed.

Protocol summary

Summary

This is a randomized blind clinical trial for comparing oral drug (Fingolimode) with high dose interferone (S.C) in treating symptoms and reduction of relapse rates in MS patients. 50 patients with inclusion criteria who were under treatment of low dose Betaferon (Cinnovex, Avonex, Actovex) and have treatment failure. (more than one relapse during one year) will be categorized in two randomized selected groups. We prescribe Fingolimode in 0.5 mg daily for the first group and Betaferon (high dose) (Rebif, Actorif, Recigen) in the second one through S.C every three days. Patients will be evaluated through months 0, 3, 9, 12, 18 (5 visits after intervention) by a neurologist who will not interfere in any parts of the study and will not be aware of which patients will take which treatment. Patients will be analyzed through E.D.S.S for surveying the intensity of disease or relapses. MRI will also be taken through months 0 and 18. At last data will be analyzed.

General information

Acronym

E.D.S.S

IRCT registration information

IRCT registration number: **IRCT2015112025146N1**

Registration date: **2016-02-18, 1394/11/29**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2016-02-18, 1394/11/29

Registrant information

Name

Pedram Moeini

Name of organization / entity

Isfahan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 31 3440 5907

Email address

pedrammoeini@resident.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Isfahan University of Medical Sciences

Expected recruitment start date

2014-10-27, 1393/08/05

Expected recruitment end date

2015-04-19, 1394/01/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

comparison of the effect of Fingolimode and Betaferon (high dose) in decreasing the symptoms and relapse rates of MS patients whose treatment with Betaferon (low dose) was failed.

Public title

comparison of Fingolimode and Betaferon (high dose) in M.S treatment

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: The most important one is MS patients who had treatment failure (relapsing rate more than one) under Betaferon (low dose); patient acceptance; non

immunosuppressive patient. Exclusion criteria:
noncooperative patient; death

Age

No age limit

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: 50

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Single blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Isfahan University of Medical
Sciences

Street address

Hezar jarib street, Darvazeshiraz square

City

Isfahan

Postal code**Approval date**

2015-01-22, 1393/11/02

Ethics committee reference number

394053

Health conditions studied**1****Description of health condition studied**

M.S

ICD-10 code

G35

ICD-10 code description

Multiple Sclerosis

Primary outcomes**1****Description**

Disability Status

Timepoint

befor intervention and 3.9.12.18 months after
intervention

Method of measurement

Check list of E.D.S.S

2**Description**

Relapse Numbers

Timepoint

0,3,9,12,18 months after intervention

Method of measurement

History and observation

Secondary outcomes

empty

Intervention groups**1****Description**

Fingolimode 0.5 mg /day will orally prescribe 18 months
for a subgroup of patients who had treatment failure with
Betaferon (low dose) during last year.

Category

Treatment - Drugs

2**Description**

Betaferon high dose s.c every 2 days will prescribe 18
months for the other subgroup of patients who had
treatment failure during last year with Betaferon (low
dose).

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

St ZAHRA Hospital

Full name of responsible person

Pedram Moeini

Street address

Sofhe street, Hakim nezami Street

City

Isfahan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Isfahan University of Medical Sciences

Full name of responsible person

Dr.Mehdi Nematbakhsh

Street address

Hezar jarib street, Darvazeshiraz square

City

Isfahan

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Isfahan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Isfahan University of Medical Sciences

Full name of responsible person

Pedram Moeini

Position

Neurology Resident

Other areas of specialty/work

Street address

Hezar jarib street, Darvazeshiraz square

City

Isfahan

Postal code

Phone

00

Fax

Email

pmoeini@yahoo.com

Web page address

www.mui.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Isfahan University of Medical Sciences

Full name of responsible person

Pedram Moeini

Position

Neurology Resident

Other areas of specialty/work

Street address

Hezar jarib street, Darvazeshiraz square

City

Isfahan

Postal code

Phone

00

Fax

Email

pmoeini@yahoo.com

Web page address

www.mui.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Isfahan University of Medical Sciences

Full name of responsible person

Pedram Moeini

Position

Neurology Resident

Other areas of specialty/work

Street address

Isfahan

City

Isfahan

Postal code

Phone

+98 913 114 7431

Fax

Email

pmoeini@yahoo.com

Web page address

www.mui.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty